Dongsung Pharmaceutical Co., Ltd. (002210) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Dongsung Pharmaceutical Co., Ltd. (002210:KRX), powered by AI.

Current Price
₩973
P/E Ratio
-3.6
Market Cap
93.8B
Sector
Healthcare
What is the Dongsung Pharmaceutical Co., Ltd. stock price forecast?

Dongsung Pharmaceutical Co., Ltd. is currently trading at ₩973. View real-time AI analysis on Alpha Lenz.

What is Dongsung Pharmaceutical Co., Ltd. insider trading activity?

View the latest insider trading data for Dongsung Pharmaceutical Co., Ltd. on Alpha Lenz.

What is Dongsung Pharmaceutical Co., Ltd.'s P/E ratio?

Dongsung Pharmaceutical Co., Ltd.'s P/E ratio is -3.6.

Dongsung Pharmaceutical Co., Ltd.

KRX · 002210
₩973+0(+0.00%)Market closedKRX regular session 09:00–15:30 KST
Ask about Dongsung Pharmaceutical Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Dongsung Pharmaceutical Co., Ltd. trades at a P/E of -3.6 (undervalued) with modest ROE of -65.5%.

Ask for details

Company Overview

Dongsung Pharmaceutical Co., Ltd. is a renowned pharmaceutical company involved in the research, development, manufacturing, and distribution of health and wellness products. The company's primary function is to enhance healthcare by providing access to a wide range of pharmaceuticals and over-the-counter medical solutions. Dongsung Pharmaceutical is particularly known for its focus on skincare, cosmetics, and dermatological products, which cater to both individual consumers and healthcare institutions. The company leverages advanced biotechnological research to develop innovative treatments that address various skin conditions and health concerns. Its products are distributed through an extensive network covering domestic and international markets, contributing significantly to the pharmaceutical sector. Based in South Korea, Dongsung Pharmaceutical plays a strategic role in the healthcare industry by supporting the delivery of accessible medicine and healthcare services across global markets. Through its continuous investment in R&D, the company sustains its competitive edge and maintains a commitment to advancing global health outcomes.

CEO나원균
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees298

Company Statistics

FY 2025

Profile

₩93,767,530,311Market Cap
₩87,168,895,110Revenue
96.37MShares Out
298Employees

Margins

42.57%Gross
-15.59%EBITDA
-11.61%Operating
-32.91%Pre-Tax
-29.53%Net

Valuation

-3.64P/E
4.01P/B
1.08EV/Sales
-11.34EV/EBITDA
-6.60P/FCF

Growth (CAGR)

-2.25%Rev 3Yr
-0.14%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-16.07%ROA
-65.53%ROE
-11.83%ROIC

Financial Health

₩3,862,703,200Cash & Cash Equivalents
₩141,209,482,380Net Debt
620.74%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Dongsung Pharmaceutical Co., Ltd. (ticker: 002210) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 298 employees. Market cap is $93.8B.

The current price is ₩973 with a P/E ratio of -3.64x and P/B of 4.01x.

ROE is -65.53% and operating margin is -11.61%. Annual revenue is $87.2B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Dongsung Pharmaceutical Co., Ltd. (002210) Stock Forecast 2026 ₩973 — Price, Financials & Analyst Targets | Alpha Lenz